Hims Hers Health Inc (HIMS)vsTeva Pharma Industries Ltd ADR (TEVA)
HIMS
Hims Hers Health Inc
$27.51
+0.26%
HEALTHCARE · Cap: $6.57B
TEVA
Teva Pharma Industries Ltd ADR
$37.09
+2.04%
HEALTHCARE · Cap: $42.84B
Smart Verdict
WallStSmart Research — data-driven comparison
Teva Pharma Industries Ltd ADR generates 572% more annual revenue ($17.32B vs $2.58B). TEVA leads profitability with a 4.1% profit margin vs -5.5%. TEVA appears more attractively valued with a PEG of 0.67. TEVA earns a higher WallStSmart Score of 49/100 (D+).
HIMS
Hold37
out of 100
Grade: F
TEVA
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-2.7%
Fair Value
$27.16
Current Price
$27.51
$0.35 premium
Intrinsic value data unavailable for TEVA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 38.2% year-over-year
Earnings expanding 72.2% YoY
Growing faster than its price suggests
Areas to Watch
Trading at 19.8x book value
Distress zone — elevated risk
Weak financial health signals
Expensive relative to growth rate
4.1% margin — thin
Operating margin of 4.0%
Premium valuation, high expectations priced in
Revenue declined 0.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : HIMS
The strongest argument for HIMS centers on Revenue Growth. Revenue growth of 38.2% demonstrates continued momentum.
Bull Case : TEVA
The strongest argument for TEVA centers on EPS Growth, PEG Ratio. PEG of 0.67 suggests the stock is reasonably priced for its growth.
Bear Case : HIMS
The primary concerns for HIMS are Price/Book, Altman Z-Score, Piotroski F-Score. Debt-to-equity of 4.77 is elevated, increasing financial risk.
Bear Case : TEVA
The primary concerns for TEVA are Profit Margin, Operating Margin, P/E Ratio. A P/E of 61.3x leaves little room for execution misses. Debt-to-equity of 2.18 is elevated, increasing financial risk.
Key Dynamics to Monitor
HIMS profiles as a hypergrowth stock while TEVA is a value play — different risk/reward profiles.
HIMS carries more volatility with a beta of 2.41 — expect wider price swings.
HIMS is growing revenue faster at 38.2% — sustainability is the question.
TEVA generates stronger free cash flow (307M), providing more financial flexibility.
Bottom Line
TEVA scores higher overall (49/100 vs 37/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Hims Hers Health Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers with licensed healthcare professionals. The company is headquartered in San Francisco, California.
Visit Website →Teva Pharma Industries Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?